17-09-2021, 03:01 PM
Sept 16 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly's (LLY.N) COVID-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.
https://www.reuters.com/world/us/fda-rev...021-09-16/
https://www.reuters.com/world/us/fda-rev...021-09-16/